Literature DB >> 21810803

Endovascular repair of type II and type III thoracoabdominal aneurysms.

Tara M Mastracci1, Matthew J Eagleton.   

Abstract

Thoracoabdominal aortic aneurysms (TAAA) remain a challenging problem to manage. Operative care for patients afflicted with this devastating problem is associated with significant risks, including renal failure and paraplegia. Several techniques have been developed to help limit the risk for these complications, yet they still remain some of the greatest hurdles associated with these procedures. Endovascular technology is rapidly advancing and may provide an alternate approach to patients with TAAA. Endograft treatment of TAAA is possible with the use of fenestrated and/or branched aortic endografts. Although still early in its evolution, we are beginning to understand some of the risks and benefits of this approach to complex aortic disease. Fenestrated and branched aortic endografting may provide an option that has lower risk to patients. Spinal cord ischemia, however, still remains a critical problem in patients who require treatment of a significant portion of their aorta. In addition, renal failure is also still observed. The mechanisms leading to the development of these complications following endograft repair, however, may not be the same as observed with open TAAA repair. This review will highlight some of our current understandings of endovascular repair of thoracoabdominal aortic aneurysms.

Entities:  

Mesh:

Year:  2011        PMID: 21810803     DOI: 10.1177/1531003511412083

Source DB:  PubMed          Journal:  Perspect Vasc Surg Endovasc Ther        ISSN: 1521-5768


  2 in total

1.  Best surgical option for thoracoabdominal aneurysm repair - the endovascular approach.

Authors:  Marcelo Ferreira; Luiz Lanziotti; Rodrigo Cunha; Guilherme d'Utra
Journal:  Ann Cardiothorac Surg       Date:  2012-09

Review 2.  [Aneurysms of the thoracic and thoracoabdominal aorta].

Authors:  J Zanow; U Settmacher
Journal:  Chirurg       Date:  2014-09       Impact factor: 0.955

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.